News (206)

Vertex Pharmaceuticals Incorporated : 2024 VRTX William Blair Growth Stock Conference Presentation vFinal PU
Transcript : Vertex Pharmaceuticals Incorporated Presents at The 44th Annual William Blair Growth Stock Conference, Jun-04-2024 04:00 PM
Vertex to Participate in Upcoming June Investor Conferences BU
Transcript : Vertex Pharmaceuticals Incorporated, Q1 2024 Earnings Call, May 06, 2024
Vertex Reports First Quarter 2024 Financial Results BU
Transcript : Vertex Pharmaceuticals Incorporated - Special Call
Transcript : Vertex Pharmaceuticals Incorporated - Special Call
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences BU
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences BU
Vertex Pharmaceuticals Incorporated : ID&E Fact Sheet PU
Vertex Pharmaceuticals - European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY, for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia AQ
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia BU
Vertex Pharmaceuticals 4Q Net, Revenue Beat Estimates DJ
Transcript : Vertex Pharmaceuticals Incorporated, Q4 2023 Earnings Call, Feb 05, 2024
Vertex Reports Fourth Quarter and Full Year 2023 Financial Results BU
Transcript : Vertex Pharmaceuticals Incorporated - Special Call
Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain BU
Vertex Announces US FDA Approval of CASGEVY for the Treatment of Transfusion-Dependent Beta Thalassemia AQ
Vertex Announces US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia BU
Vertex Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY, for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Kingdom of Saudi Arabia AQ
Vertex Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) in Kingdom of Saudi Arabia BU
Transcript : Vertex Pharmaceuticals Incorporated Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 08:15 AM
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings BU
Vertex to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8 BU
Transcript : Vertex Pharmaceuticals Incorporated - Special Call
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY for the Treatment of Sickle Cell Disease AQ
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease BU
Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY, by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia AQ
 Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia BU
Vertex Pharmaceuticals Incorporated : Q3 2023 Presentation PU
Transcript : Vertex Pharmaceuticals Incorporated, Q3 2023 Earnings Call, Nov 06, 2023
Vertex Reports Third Quarter 2023 Financial Results BU
Transcript : Vertex Pharmaceuticals Incorporated Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-13-2023 11:30 AM
Vertex to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference on September 13 BU
Vertex Appoints E. Morrey Atkinson, Ph.D., to EVP and Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations BU
Vertex Pharmaceuticals Incorporated : Q2 2023 Presentation PU
Transcript : Vertex Pharmaceuticals Incorporated, Q2 2023 Earnings Call, Aug 01, 2023
Vertex Reports Second Quarter 2023 Financial Results BU
Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes Cell Therapies AQ
Lonza and Vertex to partner to manufacture diabetes cell therapies AQ
Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies BU
Transcript : Vertex Pharmaceuticals Incorporated Presents at Goldman Sachs 44th Annual Global Healthcare Conference, Jun-13-2023 02:40 PM
FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia BU
Vertex to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 13 BU
Vertex Pharmaceuticals Incorporated : Confirms growth trajectory Our Logo
1234NextSee all

Insiders

Picture Reshma Kewalramani
Reshma Kewalramani

Reshma Kewalramani is President, Chief Executive Officer & Director at Vertex Pharmaceuticals, Inc. In the past she was VP-Global Clinical Development & Nephrology at Amgen, Inc. She received a doctorate from Boston University School of Medicine.


Picture Reshma Shetty
Reshma Shetty

Founder of Petri, Ginkgo Bioworks Holdings, Inc. and Ginkgo Bioworks, Inc., Reshma Shetty currently is President, Secretary, Treasurer & Director at Motif Food Works, Inc. and President, Chief Operating Officer & Director at Ginkgo Bioworks Holdings, Inc., President, Chief Operating Officer & Director at Ginkgo Bioworks, Inc. (a subsidiary of Ginkgo Bioworks Holdings, Inc.). She previously held the position of President, Chief Operating Officer & Director at Soaring Eagle Acquisition Corp. Dr. Shetty received a doctorate from Massachusetts Institute of Technology and an undergraduate degree from the University of Utah.


Picture Reshma Hemrajani
Reshma Hemrajani

Reshma Hemrajani has held the following positions in her career: Internal Auditor at NHPC Ltd.
since 2023, and Member at The Institute of Cost & Works Accountants of India since 1988.



Picture Kabir Kewalramani
Kabir Kewalramani

Mr. Kewalramani is the Managing Director of Berggruen Holdings India (Berggruen).
Mr. Kewalramani serves as a member of the board of Keys Hotels, Accentia Technologies, Car Club, GEAR, United Education Institutes (UEI) and Berggruen Properties.



Picture Girish Kewalramani
Girish Kewalramani

Girish Kewalramani is currently working as the Senior Vice President-Information Technology at Sahajanand Medical Technologies Ltd.


Picture Sujay Kewalramani
Sujay Kewalramani

Sujay Kewalramani is currently the Chief Executive Officer at Knowledge Marine & Engineering Works Ltd.
He completed his undergraduate degree at SUNY Maritime College and his graduate degree at the University of New Orleans.


Picture Pinkesh Kewalramani
Pinkesh Kewalramani

Pinkesh Kewalramani is currently working as the Chief Technical Officer at Knowledge Marine & Engineering Works Ltd.
He completed his undergraduate degree from Indus University.









Picture Bharat Kewalramani
Bharat Kewalramani

Bharat Kewalramani is currently the Managing Director & Director at 3D Technopack Ltd.
He previously worked as a Director at Piramal Glass Pvt Ltd.
from 2007 to 2011.



Picture Devika Kewalramani
Devika Kewalramani

Devika Kewalramani currently works at The Association of the Bar of the City of New York, as Director & Vice President from 2023.


Picture Reshma Sohoni
Reshma Sohoni

Reshma Sohoni is the founder.
She founded Seedcamp Investment Management LLP in 2007, where she currently holds the title of Managing Partner.
Ms. Sohoni also holds current positions at Credo Ventures as an advisor since 2010 and at Anthemis Group SA as a Senior Advisor since 2015.
In her former roles, she worked as a Director at Zoombu Ltd., as a Principal at Zemanta, Inc., Broadview Advisors LLC, Vodafone Corporate Ltd., SOFTBANK Europe Ventures, 3i Private Equity, Mobclix, Inc., and uberVU Ltd.
Ms. Sohoni completed her undergraduate degree at the University of Pennsylvania in 1998 and earned an MBA from INSEAD in 2003.


Picture Reshma Deshmukh
Reshma Deshmukh

Reshma Deshmukh currently works as a Manager-Business Development at Smart Information Worldwide, Inc.


Picture Reshma Khilnani
Reshma Khilnani

Reshma Khilnani is the founder of MedXT, Inc. which was founded in 2012.
She is currently a Visiting Group Partner at Y Combinator LLC since 2020 and a Venture Partner at Pioneer Fund since 2017.
Ms. Khilnani has an undergraduate and graduate degree from Massachusetts Institute of Technology.




Picture Reshma Seewooram
Reshma Seewooram

Reshma Seewooram worked as a Legal Counsel at JTC Plc from 2018 to 2021.












Picture Reshma Ramachandran
Reshma Ramachandran

Reshma Ramachandran is an Independent Non-Executive Director at Oxford Instruments Plc and ISS A.
Previously, she worked as Senior Vice President & Group Head-Transformation at Adecco Group AG from 2021 to 2023.
She also held the position of Group Vice President & Head-Engineering at ABB Ltd.
Ms. Ramachandran has a graduate degree from the Indian Institute of Technology Madras and an MBA from S.P.
Jain Institute of Management & Research.


Picture Reshma Shakya
Reshma Shakya

Reshma Shakya is currently working as the Head-Treasury at Machhapuchchhre Bank Ltd.


Picture Reshma Rangwala
Reshma Rangwala

Reshma Rangwala is currently the Chief Medical Officer & Executive Vice President at Karyopharm Therapeutics, Inc. Prior to this, she held positions as the Executive Clinical Director at Merck & Co., Inc. from 2012 to 2017, Vice President-Medical at Genmab, Inc. from 2017 to 2020, and Chief Medical Officer at Aravive, Inc. from 2020 to 2022.
Dr. Rangwala completed her undergraduate degree at Duke University and obtained her doctorate from The University of Cincinnati College of Medicine.




Picture Reshma Shringarpure
Reshma Shringarpure

Reshma Shringarpure is currently the Vice President of Clinical Research & Medical Affairs at Akero Therapeutics, Inc. She previously worked as the Director of Medical Affairs at Santarus, Inc. She earned a doctorate degree from the University of Southern California.



Picture Kanak S. Kewalramani
Kanak S. Kewalramani

Kanak S.
Kewalramani
is currently the Chief Financial Officer & Director at Knowledge Marine & Engineering Works Ltd.
She is also a Director at KMEW Offshore Pvt Ltd., Knowledge Infra Ports Pvt Ltd., Kamal Marine & Engineering Works Pvt Ltd., and Indian Ports Dredging Pvt Ltd.
Previously, she worked as a Compliance Manager at Access Healthcare Services Pvt Ltd.








Picture Reshma Saujani
Reshma Saujani

Reshma Saujani is the founder of Girls Who Code, Inc. (founded in 2012) and currently serves as the Chief Executive Officer & Chairman.
She is also the founder of Clé de Peau Beauté Co. Ltd.
Ms. Saujani's current jobs include being a Director at mParticle, Inc. since 2021 and a Trustee at The Economic Club of New York.
Her former job includes being an Ex-Officio Trustee at The Museum of Modern Art.
Ms. Saujani's education history includes graduating from Harvard Kennedy School of Government and Yale Law School for her graduate degrees, and the University of Illinois At Urbana–Champaign for her undergraduate degree.


Picture Reshma Joshi Bhikha
Reshma Joshi Bhikha

Reshma Joshi Bhikha worked as an Investment Principal at African Infrastructure Investment Managers (Pty) Ltd.
from 2015 to 2018.
Prior to that, she worked as an Investment Professional at Old Mutual Alternative Investments (Pty) Ltd.
from 2012 to 2015.
In 2020, she briefly worked as an Investment Specialist at Auckland Unlimited.
Ms. Bhikha obtained an undergraduate degree from the University of Cape Town.









Picture Reshma Ramchandani
Reshma Ramchandani

Reshma Ramchandani is currently a Director at Convergence Chemicals Pvt Ltd since 2020.
Prior to this, she worked as a Secretary & Compliance Officer at Elegant Marbles & Grani Industries Ltd.




Picture Reshma Block
Reshma Block

Reshma Block is the founder of Compass Consulting LLC, which was founded in 2010.
Ms. Block is currently the Chief Technology Officer at Tricon Residential, Inc. since 2021.
Ms. Block has held former positions as Chairman at South Asian Helpline & Referral Agency, Independent Director at Healthcare Trust of America, Inc., Director at Orange County Community Foundation (California) from 2015 to 2019, Manager at Intel Corp., Chief Information Officer at BioNovix, Inc. from 2006 to 2008, Chief Operating Officer at My Life Compass LLC from 2008 to 2010, and Vice President at Mccoy Rigby Arts Conservancy.
Ms. Block's education includes an undergraduate degree from California State Polytechnic University (Pomona) and an MBA from Pepperdine Graziadio Business School.



Picture Reshma Kalimi Casale
Reshma Kalimi Casale

Reshma Kalimi Casale worked as a Senior Analyst at Stripes LLC from 2014 to 2022.
She completed her undergraduate degree at Duke University.


Picture Reshma Suresh
Reshma Suresh

Reshma Suresh is currently working as the Head of Operations and Regulatory Affairs at Qure.ai Technologies Pvt Ltd.




Picture Reshma Poojari
Reshma Poojari

Reshma Poojari is currently working as an Associate Member at the Institute of Company Secretaries of India.
Additionally, she holds the position of Secretary & Compliance Officer at Imagicaaworld Entertainment Ltd.



Picture Reshma Block
Reshma Block

Reshma Block currently works at Hoag Memorial Hospital Presbyterian, Inc., as Director.





Picture Dinesh M. Kewalramani
Dinesh M. Kewalramani

Dinesh M.
Kewalramani
is currently the Chief Operating Officer at Knowledge Marine & Engineering Works Ltd.
He completed his undergraduate degree at SUNY Maritime College and his graduate degree at the University of New Orleans.



Picture Pankaj Sureshkumar Kewalramani
Pankaj Sureshkumar Kewalramani

Pankaj Sureshkumar Kewalramani is currently working as Secretary & Compliance Officer at Typhoon Holdings Ltd.
and as Associate Member at Institute of Company Secretaries of India.
He will also be working as Secretary & Compliance Officer at Padmanabh Industries Ltd.
starting in 2024.
Previously, he worked as Secretary & Compliance Officer at Arihant Institute Ltd.
in 2021.


Picture Reshma Karipineni
Reshma Karipineni

Ms. Karipineni joined Pinnacle upon her graduation from the Stanford Graduate School of Business in 2008.
Prior to entering business school, she was an Analyst with Suffolk Capital Management, where she provided investment analysis on over 50 publicly traded small and large cap stocks.
She was previously an Associate in the Equity Research group at Banc of America Securities, where she focused exclusively on the biotechnology industry to identify and analyze early-stage investment opportunities.
While in business school, she completed an internship in Corporate Development at Gilead Sciences.
Ms. Karipineni received her BS in Biomedical Engineering from Yale University and an MBA from the Stanford Graduate School of Business.














Picture Reshma Mahaboob
Reshma Mahaboob

Reshma Mahaboob worked as a Senior Manager-Training at CreditAccess Grameen Ltd.
and as a Group Auditor at Myrada.
She graduated from Annamalai University with a degree.



Picture Reshma Barshikar
Reshma Barshikar

Reshma Krishnan Barshikar is currently working as a Principal at Blinc Management Advisors Pvt Ltd.
Prior to this, she worked as an Associate Vice President at Avendus Capital Pvt Ltd from 2006 to 2011.
She completed her undergraduate degree from Oxford Brookes University in 1999 and obtained an MBA from the Indian School of Business in 2003.






Picture Reshma Banarse
Reshma Banarse

Reshma Banarse has worked as a Director for Vitura SA since 2020 and is also a Director for 12 Adolphus Road Flat Owners Ltd.




No results for this search

  1. Stock Market
  2. Advanced search
  3. Reshma Kewalramani